Lewes, DE -- (SBWIRE) -- 07/29/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: MannKind Corporation (NASDAQ:MNKD), Sequenom, Inc. (NASDAQ:SQNM), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Affymax, Inc. (OTCMKTS: AFFY)
MannKind Corporation (NASDAQ:MNKD) increased 3.47% and closed at $7.46 on a traded volume of 6.12 million shares, in comparison to 7.61 million shares of average trading volume. So far this year, the stock is down over 184.73%.
The company has a total market capitalization of $2.17 million and its total outstanding shares are 290.88million.
Will MNKD Continue To Move Higher? Find Out Here
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Its lead product candidate includes AFREZZA inhalation powder, an insulin that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.
Sequenom, Inc. (NASDAQ:SQNM) plunged -2.42% and closed at $3.22 on a traded volume of 5.53 million shares, whereas its average trading volume is 2.48million shares. In the last three months, the stock is down -13.21%. The Intra-day range for the stock is $3.20 and $3.32.
Will SQNM Get Buyers Even After The Recent Rally? Find Out Here
Sequenom, Inc., a life sciences company, provides genetic analysis solutions in the United States and internationally. It operates through two segments, Molecular Diagnostics and Genetic Analysis.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) dropped down -5.64% and closed at $18.57 So far in three months, the stock is up down 2.48%. The 52-week range for the stock is $15.35 and $25.40 and during the previous trading session the stock touched its highest price at $19.60. Its introductory price for the day was $19.53, with the overall traded volume of 3.97 million shares.
Will ARIA Get Buyers Even After The Recent Rally? Find Out Here
ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients.
Affymax, Inc. (OTCMKTS: AFFY), after opening its shares at the price of $1.38, jumped up 9.02% to close at $1.45 for the day. The stock moved on a traded volume of 3.56 million shares, in comparison to 757,278 shares of average trading volume.
The 52-week range for the stock is $0.78 and $27.74 and during the previous trading session the stock touched its highest price at $1.50. Its introductory price for the day was $1.38
Will AFFY Continue To Move Higher? Find Out Here
Affymax, Inc., a biopharmaceutical company, engages in discovering, developing, and delivering therapies that improve the lives of patients with kidney diseases, and other serious and life-threatening illnesses. It offers OMONTYS (peginesatide) injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.
Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/